Outlook Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Iselin, NJ
OTLK chart
What traders are saying about $OTLK
Latest postsOutlook Therapeutics, Inc. news
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Yahoo Finance ·
- Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
Yahoo Finance ·
- Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Yahoo Finance ·
- Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 183%
Yahoo Finance ·
- Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Yahoo Finance ·
- Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Yahoo Finance ·
- Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Yahoo Finance ·
- Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Yahoo Finance ·
- OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Yahoo Finance ·
- Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
Yahoo Finance ·
- Oncobiologics Q3 Earnings Call Highlights
marketbeat.com ·
- Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary
app.moby.co ·
Outlook Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $1.4M | – | – | – |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M |
| Diluted EPS | $-1.79 | $-4.06 | $-4.72 | $-0.31 |
| Total assets (year end) | $18.2M | $17.0M | $21.7M | $62.7M |
| Cash and equivalents (year end) | $8.7M | $5.7M | $10.4M | $52.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Outlook Therapeutics, Inc.
- Ticker
- OTLK (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Iselin, NJ
- Incorporated in
- DE
- Fiscal year end
- September 30
- SEC CIK
- 1649989
- Former names
- Oncobiologics, Inc.
Frequently asked questions
What exchange is Outlook Therapeutics, Inc. listed on?
Outlook Therapeutics, Inc. trades on the Nasdaq under the ticker symbol OTLK.
What industry is Outlook Therapeutics, Inc. in?
Outlook Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Outlook Therapeutics, Inc. headquartered?
Outlook Therapeutics, Inc.'s business address on file with the SEC is in Iselin, NJ.
When does Outlook Therapeutics, Inc.'s fiscal year end?
Outlook Therapeutics, Inc.'s fiscal year ends on September 30.
How much revenue did Outlook Therapeutics, Inc. report?
Outlook Therapeutics, Inc. reported $1.4M in revenue for calendar year 2025, according to its SEC filings.